Overview
- ANMAT authorized 291 pharmacology clinical investigations between January and September 2026, a total that exceeds the full-year count for 2025 and was reported on Wednesday.
- The surge is supported by a federal network of more than 700 trained health centers that lets hospitals and clinics across provinces join studies and enroll patients earlier in development.
- Regulators are modernizing review procedures and are considering 'reliance,' a process that uses prior scientific assessments from reference agencies such as the U.S. FDA to avoid duplicate reviews while keeping safety and quality checks.
- Authorities say approvals do not equal market authorizations, and ANMAT has continued enforcement and oversight this year, including 202 sanction measures and 183 health alerts, plus faster vaccine lot-release times.
- Around 80,000 Argentine patients now take part in trials, local centers are joining high-profile international studies such as retatrutide obesity research, and experts say the growth raises investment and data-export opportunities while demanding more trained staff and ethical oversight.